Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I.
Learn how representative samples and random samples differ and why combining them minimizes sampling bias for accurate data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results